Mayne Pharma Group Limited (MAYNF)
USD 4.25
(3.41%)
USD 4.25
(3.41%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -45.85 Million AUD | 75.4% |
| 2023 | -186.44 Million AUD | -1747.61% |
| 2022 | 11.31 Million AUD | 55.42% |
| 2021 | 7.28 Million AUD | 108.33% |
| 2020 | 3.49 Million AUD | -77.37% |
| 2019 | 15.44 Million AUD | -62.03% |
| 2018 | 40.66 Million AUD | -72.45% |
| 2017 | 147.62 Million AUD | 182.41% |
| 2016 | 52.27 Million AUD | 204.14% |
| 2015 | 17.18 Million AUD | -46.9% |
| 2014 | 32.37 Million AUD | 1888.39% |
| 2013 | 1.62 Million AUD | -81.52% |
| 2012 | 8.81 Million AUD | 262.89% |
| 2011 | 2.42 Million AUD | 16.46% |
| 2010 | 2.08 Million AUD | 150.22% |
| 2009 | -4.15 Million AUD | -18.78% |
| 2008 | -3.49 Million AUD | -91.1% |
| 2007 | -1.82 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -18.96 Million AUD | 70.45% |
| 2024 Q3 | -3.62 Million AUD | 90.66% |
| 2024 Q4 | -3.62 Million AUD | 0.0% |
| 2024 FY | -77.83 Million AUD | 58.25% |
| 2024 Q2 | -38.83 Million AUD | -104.74% |
| 2023 FY | -186.44 Million AUD | -1747.61% |
| 2023 Q3 | -31.85 Million AUD | 73.94% |
| 2023 Q1 | -52.85 Million AUD | -38.69% |
| 2023 Q2 | -122.26 Million AUD | -131.32% |
| 2023 Q4 | -64.18 Million AUD | -101.47% |
| 2022 Q3 | -38.97 Million AUD | -60.7% |
| 2022 Q2 | -24.25 Million AUD | -8.78% |
| 2022 FY | 11.31 Million AUD | 55.42% |
| 2022 Q1 | -22.29 Million AUD | -2499.68% |
| 2022 Q4 | -38.11 Million AUD | 2.21% |
| 2021 Q3 | -5.24 Million AUD | -1308.87% |
| 2021 Q4 | 929 Thousand AUD | 117.71% |
| 2021 Q1 | -955.5 Thousand AUD | 81.82% |
| 2021 FY | 7.28 Million AUD | 108.33% |
| 2021 Q2 | 434 Thousand AUD | 145.42% |
| 2020 Q4 | -5.25 Million AUD | 4.58% |
| 2020 FY | 3.49 Million AUD | -77.37% |
| 2020 Q1 | -1.05 Million AUD | 77.31% |
| 2020 Q2 | -6.87 Million AUD | -549.81% |
| 2020 Q3 | -5.5 Million AUD | 19.89% |
| 2019 Q1 | 11.59 Million AUD | -67.08% |
| 2019 FY | 15.44 Million AUD | -62.03% |
| 2019 Q4 | -4.66 Million AUD | -315.41% |
| 2019 Q3 | -1.12 Million AUD | -109.68% |
| 2019 Q2 | 11.59 Million AUD | 0.0% |
| 2018 Q3 | 35.22 Million AUD | 1325.25% |
| 2018 Q1 | -2.87 Million AUD | -112.18% |
| 2018 FY | 40.66 Million AUD | -72.45% |
| 2018 Q4 | 35.22 Million AUD | 0.0% |
| 2018 Q2 | -2.87 Million AUD | 0.0% |
| 2017 Q1 | 34.88 Million AUD | 176.78% |
| 2017 FY | 147.62 Million AUD | 182.41% |
| 2017 Q2 | 34.88 Million AUD | 0.0% |
| 2017 Q3 | 23.61 Million AUD | -32.32% |
| 2017 Q4 | 23.61 Million AUD | 0.0% |
| 2016 Q4 | 12.6 Million AUD | 0.0% |
| 2016 Q3 | 12.6 Million AUD | 22.22% |
| 2016 Q2 | 10.31 Million AUD | 0.0% |
| 2016 Q1 | 10.31 Million AUD | 142.5% |
| 2016 FY | 52.27 Million AUD | 204.14% |
| 2015 Q3 | 4.25 Million AUD | 22.87% |
| 2015 Q2 | 3.46 Million AUD | 0.0% |
| 2015 Q4 | 4.25 Million AUD | 0.0% |
| 2015 FY | 17.18 Million AUD | -46.9% |
| 2015 Q1 | 3.46 Million AUD | -59.57% |
| 2014 Q4 | 8.56 Million AUD | 0.0% |
| 2014 Q2 | 6.83 Million AUD | 0.0% |
| 2014 Q3 | 8.56 Million AUD | 25.33% |
| 2014 FY | 32.37 Million AUD | 1888.39% |
| 2014 Q1 | 6.83 Million AUD | 73.6% |
| 2013 Q4 | 3.93 Million AUD | 0.0% |
| 2013 Q3 | 3.93 Million AUD | 0.0% |
| 2013 FY | 1.62 Million AUD | -81.52% |
| 2012 FY | 8.81 Million AUD | 262.89% |
| 2011 FY | 2.42 Million AUD | 16.46% |
| 2010 FY | 2.08 Million AUD | 150.22% |
| 2009 FY | -4.15 Million AUD | -18.78% |
| 2008 FY | -3.49 Million AUD | -91.1% |
| 2007 FY | -1.82 Million AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AstraZeneca PLC | 8.19 Billion USD | 100.56% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.24 Billion USD | 100.266% |
| CSPC Pharmaceutical Group Limited | 7.01 Billion USD | 100.654% |
| Clarus Therapeutics Holdings, Inc. | -39.73 Million USD | -15.413% |
| Novartis AG | 9.76 Billion USD | 100.469% |
| PT Kalbe Farma Tbk. | 3625.13 Billion USD | 100.001% |